Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 160

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 160
---
 of ten years.

Compensation expense related to awards to employees is calculated on a straight-line basis by recognizing the grant date fair value over the associated service period of the award, which is generally the vesting term. For the years ended December 31, 2024 and 2023, we recognized share‑based compensation expense in the statements of operations and comprehensive loss as follows (in thousands):

Year Ended December 31,20242023Selling, general and administrative$6,782 $7,450 Research and development4,057 4,504 Total$10,839 $11,954 

As of December 31, 2024, total unrecognized compensation cost related to stock options was $9.9 million which we expect to recognize over a weighted average period of 1.8 years. As of December 31, 2024, there was $0.4 million of 

112

unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 3.2 years. The intrinsic value of all outstanding stock options and restricted stock units as of December 31, 2024 was $1.8 million and $0.8 million, respectively. 

Recent Accounting Pronouncements

See Note 2 to the consolidated financial statements for a discussion of recent accounting pronouncements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required by this Item.

Item 8. Financial Statements and Supplementary Data. 

Beginning on the following page are the consolidated financial statements with applicable notes and the related Report of Independent Registered Public Accounting Firm.

113

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm (BDO USA, P.C., San Diego, CA, PCAOB ID#243)115Consolidated Balance Sheets as of December 31, 2024 and 2023117Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2024 and 2023118Consolidated Statements of Stockholders’ Equity for the Years ended December 31, 2024 and 2023119Consolidated Statements of Cash Flows for the Years ended December 31, 2024 and 2023120Notes to Consolidated Financial Statements122

114

Report of Independent Registered Public Accounting